NDA 021165 · Organon
Clarinex
Desloratadine · Oral · Histamine-1 Receptor Antagonist
NovelLast checked: Nov 20, 2026Latest source record: Mar 15, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2001
Dec 21, 2001
Approved uses
1
Original approval plus efficacy supplements
Registered trials
87
28 Phase 3, 4 recruiting
FAERS reports
10,834
8,441 serious, 608 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 17, 2025.
CLARINEX is a histamine-1 (H1) receptor antagonist indicated for: Seasonal Allergic Rhinitis: relief of nasal and non-nasal symptoms in patients 2 years of age and older. ( 1.1 ) Perennial Allergic Rhinitis: relief of nasal and non-nasal symptoms in patients 6 months of age and older. ( 1.2 ) Chronic Idiopathic Urticaria: symptomatic relief of pruritus, reduction in the number of hives, and size of hives in patients 6 months of age and older. ( 1.3 ) 1.1 Seasonal Allergic Rhinitis CLARINEX ® is indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis in patients 2 years of age and older. 1.2 Perennial Allergic Rhinitis CLARINEX is indicated for the relief of the nasal and non-nasal symptoms of perennial allergic rhinitis in patients 6 months of age and older. 1.3 Chronic Idiopathic Urticaria CLARINEX is indicated for the symptomatic relief of pruritus, reduction in the number of hives, and size of hives, in patients with chronic idiopathic urticaria 6 months of age and older.
Mechanism: Desloratadine is a long-acting tricyclic histamine antagonist with selective H 1 -receptor histamine antagonist activity. Receptor binding data indicates that at a concentration of 2–3 ng/mL (7 nanomolar), desloratadine shows significant interaction with the human histamine H 1 -receptor. Desloratadine inhibited histamine release from human mast cells in vitro . Results of a radiolabeled tissue distribution study in rats and a radioligand H 1 -receptor binding study in guinea pigs showed that desloratadine did not readily cross the blood brain barrier. The clinical significance of this...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- CLARINEX · DESLORATADINE 5MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Desloratadine" as an intervention, any sponsor and status, largest first.
- CUTE (Chronic Urticaria Treatment Evaluation)Pivotal-lookingCompleted
UCB PharmaUCB
NCT00264303 · 886 participants · Start Dec 2005 · Primary completion Jan 2007
Drug: Levocetirizine; Desloratadine · For: Chronic Idiopathic Urticaria
Sites: Bruges, Belgium; Brussels, Belgium; Liège, Belgium · 80 sites in all
- LEADER (LEvocetirizine And DEsloratadine in Allergic Rhinitis)Pivotal-lookingCompleted
UCB PharmaUCB
NCT00160589 · 729 participants · Start Apr 2005 · Primary completion Sep 2005
Drug: Levocetirizine · For: Rhinitis, Allergic, Perennial
- Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR) (Study P04054)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00783146 · 728 participants · Start Aug 1, 2004 · Primary completion Oct 1, 2004
Drug: desloratadine; fexofenadine and 1 more · For: Seasonal Allergic Rhinitis
- Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR)(Study P04053)(COMPLETED)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00783211 · 722 participants · Start Aug 1, 2004 · Primary completion Oct 1, 2004
Drug: desloratadine; fexofenadine and 1 more · For: Seasonal Allergic Rhinitis
- A Phase III Efficacy Study of the Symptomatic Treatment of Seasonal Allergic Rhinitis With BilastinePivotal-lookingCompleted
Faes Farma, S.A.Industry
NCT01108783 · 720 participants · Start Apr 2003 · Primary completion Aug 2003
Drug: Bilastine; Desloratadine and 1 more · For: Seasonal Allergic Rhinitis
- Study for the Treatment of Persistent Allergic Rhinitis With Desloratadine (Study P04684)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00405964 · 716 participants · Start Sep 2006 · Primary completion Apr 2008
Drug: 5-mg Desloratadine; Placebo tablet · For: Allergic Rhinitis
- A Study of the Efficacy and Safety of Desloratadine (MK-4117) in Japanese Participants With Perennial Allergic Rhinitis (MK-4117-200)Pivotal-lookingCompleted
Organon and CoIndustry
NCT01918033 · 608 participants · Start Aug 20, 2013 · Primary completion Jan 26, 2014
Drug: Desloratadine 5 mg; Placebo · For: Perennial Allergic Rhinitis
- Study for the Treatment of Intermittent Allergic Rhinitis With Desloratadine (Study P04683)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00406783 · 547 participants · Start Aug 2006 · Primary completion Nov 2007
Drug: 5-mg Desloratadine; Placebo · For: Rhinitis, Allergic, Seasonal; Rhinitis, Allergic, Perennial
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective630
- fatigue629
- nausea607
- dyspnoea544
- headache485
- diarrhoea471
- dizziness458
- pruritus445
- vomiting417
- rash396
- off label use357
- pyrexia333
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 467 |
| 2005 | 347 |
| 2006 | 311 |
| 2007 | 355 |
| 2008 | 292 |
| 2009 | 283 |
| 2010 | 341 |
| 2011 | 444 |
| 2012 | 459 |
| 2013 | 255 |
| 2014 | 246 |
| 2015 | 425 |
| 2016 | 480 |
| 2017 | 401 |
| 2018 | 628 |
| 2019 | 738 |
| 2020 | 653 |
| 2021 | 516 |
| 2022 | 683 |
| 2023 | 601 |
| 2024 | 764 |
| 2025 | 603 |
| 2026 | 542 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Clarinex (Desloratadine)
2024 spending
$252K
Beneficiaries
124
457 claims
Per beneficiary
$2,035
$7.99 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $6,774 |
| 2022 | $402,646 |
| 2023 | $289,142 |
| 2024 | $252,395 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative Efficacy of Mometasone Nasal Spray Combined with Different Doses of Desloratadine, and Montelukast in Childhood Allergic Rhinitis: A Randomized Clinical Trial.
Ghanbari N, Eftekhari K, Samadzadeh-Mamaghani M, et al. · Iran J Allergy Asthma Immunol 2024 · Randomized Controlled Trial, Comparative Study
- A treatment for allergic rhinitis: a view on the role of levocetirizine.
Holgate S, Powell R, Jenkins M, et al. · Curr Med Res Opin 2005 · Meta-Analysis, Research Support, Non-U.S. Gov't
- H1-Antihistamine Premedication in NSAID-Associated Urticaria.
Trautmann A, Anders D, Stoevesandt J · J Allergy Clin Immunol Pract 2016 · Clinical Trial
- H1-antihistamines for chronic spontaneous urticaria.
Sharma M, Bennett C, Cohen SN, et al. · Cochrane Database Syst Rev 2014 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Efficacy and Safety of Up-dosing Antihistamines in Chronic Spontaneous Urticaria: A Systematic Review of the Literature.
Iriarte Sotés P, Armisén M, Usero-Bárcena T, et al. · J Investig Allergol Clin Immunol 2021 · Systematic Review
- Sedative Effects of Levocetirizine: A Systematic Review and Meta-Analysis of Randomized Controlled Studies.
Snidvongs K, Seresirikachorn K, Khattiyawittayakun L, et al. · Drugs 2017 · Meta-Analysis, Systematic Review
Sponsor: Organon
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.